# Kardigan Inc. (KARD) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $14.32, market value $1.3 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Kardigan Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 2.2×**. The shares trade at 2.2× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -11.8%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: 76.7%**. A 76.7% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.

## Growth
- **EPS growth (1 yr): -124.9%**. Earnings per share fell 124.9%.

## Financial health
- **Current ratio: 9.20** (quick 9.20). Current assets cover the next year's liabilities 9.20 times.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Kardigan Inc. does not currently pay a dividend, but it returned -33.9% of its market value through buybacks over the last year.

## Analyst view
- **Analyst consensus: strong_buy** (7 analysts). 7 analysts cover Kardigan Inc.; the consensus is strong_buy, with an average price target of $41.00 (+186% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **From 52-week high: -47.0%** (17.1% above the low). Trading 47% below its 52-week high, deep in a drawdown.
- **RSI (14-day): 49**. An RSI of 49 is neutral.
- **Beta (1 yr): 1.54** (volatility 70%). Beta of 1.54 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=KARD · Page: https://foliofundamentals.com/stocks/kard

Not investment advice.